CommuniTreat

Company Overview

Snapshot

Founded in April 2021 by Nimrod Dahan, Itay Ben Mordechai, Dr. Tami Ehrmann Barr, and Dr. Hilik Marom, CommuniTreat operates with 1–10 employees. The company has secured funding across two rounds, with Menmon leading a Pre-Seed round in April 2022.

Business overview

CommuniTreat is developing an IP-backed bio-formula solution focused on the strategic control of feral and invasive species populations. The company's core technology involves a food-based contraceptive designed to reduce the reproductive rate of these species, thereby mitigating ecological and public health risks. CommuniTreat aims to restore balance in human-animal interactions by positioning fertility control as a cornerstone of integrated pest management, serving markets globally, including the United States and Europe, within the Agriculture & Food Technologies sector.

Company Intelligence Q&A

What is CommuniTreat's primary focus?

CommuniTreat focuses on the strategic control of feral and invasive species populations through an IP-backed bio-formula solution.

When was CommuniTreat founded and by whom?

CommuniTreat was founded in April 2021 by Nimrod Dahan, Itay Ben Mordechai, Dr. Tami Ehrmann Barr, and Dr. Hilik Marom.

What is CommuniTreat's core technology?

CommuniTreat's core technology is a food-based contraceptive designed to reduce the reproductive rate of feral and invasive species.

Which markets does CommuniTreat target?

CommuniTreat targets global markets, including the United States and Europe, with its solutions for pest management.

Has CommuniTreat received any funding?

In April 2022, CommuniTreat secured Pre-Seed funding, with Menmon participating as a lead investor.